Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin.

Vanderheiden A, Harrison LB, Warshauer JT, Adams-Huet B, Li X, Yuan Q, Hulsey K, Dimitrov I, Yokoo T, Jaster AW, Pinho DF, Pedrosa I, Lenkinski RE, Pop LM, Lingvay I

The Journal of clinical endocrinology and metabolism24 Feb 2016Cited by 62 (Europe PMC)

PMID26909799DOI10.1210/jc.2015-3906PepBankPUB-26909799

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with long-standing type 2 diabetes on high-dose insulin, adding liraglutide lowered HbA1c more than placebo.
In plain wordsIn adults with long-standing type 2 diabetes on high-dose insulin, adding liraglutide lowered HbA1c more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n = 71
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/d · 6 monthsAs given in this study (human).
Measurements
HbA1c treatment difference
−0.9%
liraglutide vs placebo
Source sentences
Summary
Glycosylated hemoglobin improved significantly with liraglutide treatment, with an end-of-trial estimated treatment difference between groups of −0.9% (95% confidence interval, −1.5, −0.4%) (P = .002).
3 context sentences(design, population, supporting numbers)
Summary · context
A single-center, randomized, double-blind, placebo-controlled trial.
Summary · context
Seventy-one patients with long-standing (median, 17 years) T2D requiring high-dose insulin treatment (>1.5 U/kg/d; average, 2.2 ± 0.9 U/kg/d).
Summary · context
Patients were randomized to liraglutide 1.8 mg/d or matching placebo for 6 months.
Report a problemFND-2690979901
02HumanRandomized controlled trialEfficacy outcome
In adults with long-standing type 2 diabetes on high-dose insulin, liraglutide improved insulin secretion, measured as C-peptide area under the curve, compared with placebo.
In plain wordsIn adults with long-standing type 2 diabetes on high-dose insulin, liraglutide improved insulin secretion more than placebo did.
Peptide
Liraglutide
Outcome
IncreaseInsulin secretion (C-peptide AUC)
Study
n = 71
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
1.8 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
Insulin secretion improved in the liraglutide group vs placebo, as measured by the area under the curve of C-peptide (P = .002) and the area under the curves ratio of C-peptide to glucose (P = .003).
3 context sentences(design, population, supporting numbers)
Summary · context
A single-center, randomized, double-blind, placebo-controlled trial.
Summary · context
Seventy-one patients with long-standing (median, 17 years) T2D requiring high-dose insulin treatment (>1.5 U/kg/d; average, 2.2 ± 0.9 U/kg/d).
Summary · context
Patients were randomized to liraglutide 1.8 mg/d or matching placebo for 6 months.
Report a problemFND-2690979902
03HumanRandomized controlled trialEfficacy outcome
In adults with long-standing type 2 diabetes on high-dose insulin, liraglutide improved the area under the curves ratio of C-peptide to glucose compared with placebo.
In plain wordsIn adults with long-standing type 2 diabetes on high-dose insulin, liraglutide improved a second measure of insulin secretion more than placebo did.
Peptide
Liraglutide
Outcome
IncreaseInsulin secretion (C-peptide to glucose AUC ratio)
Study
n = 71
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
1.8 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
Insulin secretion improved in the liraglutide group vs placebo, as measured by the area under the curve of C-peptide (P = .002) and the area under the curves ratio of C-peptide to glucose (P = .003).
3 context sentences(design, population, supporting numbers)
Summary · context
A single-center, randomized, double-blind, placebo-controlled trial.
Summary · context
Seventy-one patients with long-standing (median, 17 years) T2D requiring high-dose insulin treatment (>1.5 U/kg/d; average, 2.2 ± 0.9 U/kg/d).
Summary · context
Patients were randomized to liraglutide 1.8 mg/d or matching placebo for 6 months.
Report a problemFND-2690979903
04HumanRandomized controlled trialEfficacy outcome
In adults with long-standing type 2 diabetes on high-dose insulin, insulin sensitivity did not differ significantly between liraglutide and placebo.
In plain wordsIn adults with long-standing type 2 diabetes on high-dose insulin, liraglutide did not change insulin sensitivity compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeInsulin sensitivity (Matsuda index)
Study
n = 71
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
Insulin sensitivity (Matsuda index) and glucagon secretion did not change significantly between groups.
3 context sentences(design, population, supporting numbers)
Summary · context
A single-center, randomized, double-blind, placebo-controlled trial.
Summary · context
Seventy-one patients with long-standing (median, 17 years) T2D requiring high-dose insulin treatment (>1.5 U/kg/d; average, 2.2 ± 0.9 U/kg/d).
Summary · context
Patients were randomized to liraglutide 1.8 mg/d or matching placebo for 6 months.
Report a problemFND-2690979904
05HumanRandomized controlled trialEfficacy outcome
In adults with long-standing type 2 diabetes on high-dose insulin, glucagon secretion did not differ significantly between liraglutide and placebo.
In plain wordsIn adults with long-standing type 2 diabetes on high-dose insulin, liraglutide did not change glucagon secretion compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeGlucagon secretion
Study
n = 71
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
1.8 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
Insulin sensitivity (Matsuda index) and glucagon secretion did not change significantly between groups.
3 context sentences(design, population, supporting numbers)
Summary · context
A single-center, randomized, double-blind, placebo-controlled trial.
Summary · context
Seventy-one patients with long-standing (median, 17 years) T2D requiring high-dose insulin treatment (>1.5 U/kg/d; average, 2.2 ± 0.9 U/kg/d).
Summary · context
Patients were randomized to liraglutide 1.8 mg/d or matching placebo for 6 months.
Report a problemFND-2690979905
06HumanRandomized controlled trialEfficacy outcome
In adults with long-standing type 2 diabetes on high-dose insulin, liver fat decreased with liraglutide compared with placebo.
In plain wordsIn adults with long-standing type 2 diabetes on high-dose insulin, liraglutide reduced liver fat more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseLiver fat
Study
n = 71
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
1.8 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
Liver fat and sc fat decreased in the liraglutide group vs placebo (P = .0006 and P = .01, respectively), whereas neither visceral nor pancreatic fat changed significantly.
3 context sentences(design, population, supporting numbers)
Summary · context
A single-center, randomized, double-blind, placebo-controlled trial.
Summary · context
Seventy-one patients with long-standing (median, 17 years) T2D requiring high-dose insulin treatment (>1.5 U/kg/d; average, 2.2 ± 0.9 U/kg/d).
Summary · context
Patients were randomized to liraglutide 1.8 mg/d or matching placebo for 6 months.
Report a problemFND-2690979906
07HumanRandomized controlled trialEfficacy outcome
In adults with long-standing type 2 diabetes on high-dose insulin, subcutaneous fat decreased with liraglutide compared with placebo.
In plain wordsIn adults with long-standing type 2 diabetes on high-dose insulin, liraglutide reduced fat under the skin more than placebo did.
Peptide
Liraglutide
Outcome
DecreaseSubcutaneous fat
Study
n = 71
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
1.8 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
Liver fat and sc fat decreased in the liraglutide group vs placebo (P = .0006 and P = .01, respectively), whereas neither visceral nor pancreatic fat changed significantly.
3 context sentences(design, population, supporting numbers)
Summary · context
A single-center, randomized, double-blind, placebo-controlled trial.
Summary · context
Seventy-one patients with long-standing (median, 17 years) T2D requiring high-dose insulin treatment (>1.5 U/kg/d; average, 2.2 ± 0.9 U/kg/d).
Summary · context
Patients were randomized to liraglutide 1.8 mg/d or matching placebo for 6 months.
Report a problemFND-2690979907
08HumanRandomized controlled trialEfficacy outcome
In adults with long-standing type 2 diabetes on high-dose insulin, visceral fat did not change significantly with liraglutide compared with placebo.
In plain wordsIn adults with long-standing type 2 diabetes on high-dose insulin, liraglutide did not change belly organ fat compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeVisceral fat
Study
n = 71
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
1.8 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
Liver fat and sc fat decreased in the liraglutide group vs placebo (P = .0006 and P = .01, respectively), whereas neither visceral nor pancreatic fat changed significantly.
3 context sentences(design, population, supporting numbers)
Summary · context
A single-center, randomized, double-blind, placebo-controlled trial.
Summary · context
Seventy-one patients with long-standing (median, 17 years) T2D requiring high-dose insulin treatment (>1.5 U/kg/d; average, 2.2 ± 0.9 U/kg/d).
Summary · context
Patients were randomized to liraglutide 1.8 mg/d or matching placebo for 6 months.
Report a problemFND-2690979908
09HumanRandomized controlled trialEfficacy outcome
In adults with long-standing type 2 diabetes on high-dose insulin, pancreatic fat did not change significantly with liraglutide compared with placebo.
In plain wordsIn adults with long-standing type 2 diabetes on high-dose insulin, liraglutide did not change pancreatic fat compared with placebo.
Peptide
Liraglutide
Outcome
No significant changePancreatic fat
Study
n = 71
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
1.8 mg/d · 6 monthsAs given in this study (human).
Source sentences
Summary
Liver fat and sc fat decreased in the liraglutide group vs placebo (P = .0006 and P = .01, respectively), whereas neither visceral nor pancreatic fat changed significantly.
3 context sentences(design, population, supporting numbers)
Summary · context
A single-center, randomized, double-blind, placebo-controlled trial.
Summary · context
Seventy-one patients with long-standing (median, 17 years) T2D requiring high-dose insulin treatment (>1.5 U/kg/d; average, 2.2 ± 0.9 U/kg/d).
Summary · context
Patients were randomized to liraglutide 1.8 mg/d or matching placebo for 6 months.
Report a problemFND-2690979909

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01505673

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

Ildiko Lingvayn = 71Jan 2012 to Jun 2016

Type 2 Diabetes Mellitus · Obesity

Trial page ClinicalTrials.govUpdated 16 Jan 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.